Trial Profile
A Randomized, Double-blinded, Multicenter Study to Evaluate the Antiviral Efficacy and Safety of Adding the HCV Polymerase Inhibitor Prodrug (RO5024048) for 24 Weeks to the Currently Approved Combination of Pegasys and Copegus in Treatment-Naive Patients With Chronic Hepatitis C Genotype 1 or 4
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 03 Aug 2016
Price :
$35
*
At a glance
- Drugs Mericitabine (Primary) ; Peginterferon alfa-2a; Ribavirin
- Indications Hepatitis C
- Focus Therapeutic Use
- Acronyms JUMP-C
- Sponsors Roche
- 22 Aug 2012 Actual patient number changed from 168 to 168168 as reported by ClinicalTrials.gov.
- 22 Aug 2012 Actual end date (Jun 2012) added as reported by ClinicalTrials.gov.
- 30 Jun 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.